NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain
April 24, 2023 11:00 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 24, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has formally secured exclusive worldwide rights from the University...
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board
April 18, 2023 09:15 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 18, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory...
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
April 04, 2023 14:00 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...
Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
April 03, 2023 07:00 ET
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
March 06, 2023 08:00 ET
|
NeOnc Technologies Holdings, Inc.
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
NeOnc Technologies Completes $10.0 Million Equity Funding Round
February 08, 2023 11:00 ET
|
NeOnc Technologies Holdings, Inc
LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has completed a $10.0 million equity funding round at a post-money...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
November 17, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Global Gene and Cell Therapies Targeting CNS Disorders Market 2021-2026 Featuring Emerging Drugs - NurOwn (BrainStorm Cell Therapeutics) & Neuro-Cells (Neuroplast)
May 26, 2021 06:18 ET
|
Research and Markets
Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Gene and Cell Therapies Targeting CNS Disorders - Market Insights and Market Forecast - 2026" report has been added to ResearchAndMarkets.com's...
Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast Report 2017-2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan
January 05, 2021 04:38 ET
|
Research and Markets
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) -- The "Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's...
Press Briefing on Recent Clinical and Preclinical Advances in Focused Ultrasound
October 18, 2018 14:24 ET
|
Focused Ultrasound Foundation
Charlottesville, VA, Oct. 18, 2018 (GLOBE NEWSWIRE) -- WHAT: A briefing featuring key data presented at the 6th International Symposium on Focused Ultrasound, the world's leading forum dedicated to...